Gut Bacteria Transplants Show Promise for Treating Parkinson's Disease Symptoms

This groundbreaking clinical trial investigated whether resetting the gut microbiome through fecal microbiota transplantation (FMT) could slow Parkinson's disease progression and improve symptoms. The research addresses mounting evidence that Parkinson's may actually originate in the gut, where alpha-synuclein protein aggregation begins before spreading to the brain.

The randomized controlled study enrolled 49 Parkinson's patients at University Ghent, running from December 2020 to December 2022. Participants received either donor FMT from healthy individuals or autologous FMT using their own bacteria as a control group. Researchers measured gut bacteria composition, intestinal inflammation markers, and various Parkinson's symptoms throughout the study period.

The trial builds on consistent findings that Parkinson's patients have distinct gut microbiome patterns compared to healthy individuals. Gastrointestinal dysfunction often precedes classic motor symptoms by several years, suggesting the gut-brain connection plays a crucial role in disease development. By transplanting healthy gut bacteria, researchers aimed to restore normal gut function and potentially slow disease progression.

While specific results haven't been fully published, this completed study represents a significant step toward understanding whether microbiome interventions can meaningfully impact neurodegenerative diseases. The research has important implications for longevity and healthy aging, as it explores whether relatively simple gut health interventions could prevent or slow one of the most common age-related neurological conditions affecting millions worldwide.